SCHEMBL2178609

SCHEMBL2178609

CC(C)C(C(=O)O)N1Cc2ccc(-c3ccc(NC(=O)c4ccc(C(C)(C)C)cc4)cn3)cc2C1=O

nearest known ligand 0.43

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 5/20 0.43
TRPV1 Q8NER1 2/20 0.42
PTPN1 P18031 2/20 0.41
PTPN2 P17706 1/20 0.41
ITGB3 P05106 2/20 0.41
ITGA2B P08514 2/20 0.41
ITGA2 P17301 2/20 0.41
PTPN6 P29350 1/20 0.41
PTPN11 Q06124 1/20 0.41
NR1H4 Q96RI1 1/20 0.40
GALR3 O60755 1/20 0.38
MAPK1 P28482 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2178734 1.00 DGAT1 (0.43) DGAT1TRPV1PTPN1PTPN2ITGB3
SCHEMBL2177652 0.92 PTPN1 (0.47) DGAT1PTPN1PTPN2ITGB3ITGA2B
SCHEMBL13718837 0.92 PTPN1 (0.47) DGAT1PTPN1PTPN2ITGB3ITGA2B
SCHEMBL2181128 0.89 NR1H4 (0.47) DGAT1TRPV1ITGB3ITGA2BITGA2
SCHEMBL2181046 0.89 NR1H4 (0.47) DGAT1TRPV1ITGB3ITGA2BITGA2
SCHEMBL2179228 0.88 MAP3K5 (0.40) DGAT1TRPV1ITGB3ITGA2BITGA2
SCHEMBL2182144 0.88 MAP3K5 (0.40) DGAT1TRPV1ITGB3ITGA2BITGA2
SCHEMBL2181152 0.87 DGAT1 (0.42) DGAT1TRPV1PTPN1PTPN2ITGB3
SCHEMBL2176996 0.87 DGAT1 (0.42) DGAT1TRPV1PTPN1PTPN2ITGB3
SCHEMBL13719175 0.86 MEN1 (0.43) DGAT1ITGB3ITGA2BITGA2NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT DGAT1 1/4885TRPV1 2047/4885PTPN1 2065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.